Duopharma Biotech may trend higher after it broke above the RM1.50 resistance and hit its 7-month high a few sessions ago.
With the 20-day EMA remaining above the 50-day EMA since the bullish crossover in late October, the uptrend may continue in
the near term. A bullish bias may emerge above the RM1.50 level, with a stop-loss set at RM1.42, below the 50-day EMA.
Towards the upside, the near-term resistance level is seen at RM1.70, followed by RM1.80.

Entry : RM1.50–1.58

Target : RM1.70, RM1.80

Exit : RM1.42

Source: AmInvest Research - 21 Dec 2022